Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
Completed · Phase 4
Conditions studied: Sarcoidosis, Pulmonary Arterial Hypertension
In brief
This trial will study the treatment of sarcoidosis-associated pulmonary arterial hypertension with inhaled iloprost, a drug approved for primary pulmonary arterial hypertension.
Key facts
- Study ID
- NCT00403650
- Run by
- University of Cincinnati
- People needed
- 20
- Starts
- 2006-11-01
- Expected to finish
- 2008-09-01
- Last updated by the study team
- 2013-04-12
Who can join
Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients with known sarcoidosis 17
- Age 18 or greater
- Patients with documented pulmonary hypertension with a PA mean > 25 mm as measured by cardiac catheterization within six months of entry into the study
- Patients with dyspnea
- Six minute walk distance of between 100 to 500 meters
- Patients on stable immunotherapy for their sarcoidosis, including prednisone, methotrexate, azathioprine, hydroxychloroquine, cyclophosphamide, thalidomide, and/or infliximab
- Patients able to provide written consent
You may not qualify if…
- Patients on pulmonary vasodilator drugs (flolan, remodulin, bosentan, sildenafil) in the prior 28 days (patients on stable dose of calcium channel blocker for more than 1 month prior to right heart catheterization can be continued on the calcium channel blocker)
- Patients with severe airway obstruction as defined by FEV1/FVC of less than 35%
- Patients with World Health Organization (WHO) class IV status
- Patients who are pregnant or breast feeding
- Patients with significant left ventricular dysfunction with a left ventricular ejection fraction of less than 35%
- Significant liver dysfunction not due to sarcoidosis
- Patients with severe other organ disease felt by investigators to impact survival during the course of the study
- Patients unable to perform the 6 inhalation treatments required for therapy
- Patients with < 90 mm Hg Systolic systemic blood pressure will be excluded
Where it is running
- University of Cincinnati — Cincinnati, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.